Capital Law’s Corporate team have advised Swansea-based medical device company, PulmonIR, on £105,000 funding.
Innovate UK granted PulmonIR the funds, which will allow it to carry out product development work before running clinical trials and securing regulatory approval – in the UK, EU, US and China – for its technology to help detect and monitor lung disease. The company’s development plans are supported by access to a portfolio of patent applications relating to the use of infrared spectroscopy to diagnose and monitor respiratory conditions.
Dr Mark Bowman, CEO of PulmonIR Ltd said, ‘we have just completed a further venture capital investment round to match our recent Innovate UK Investment Accelerator award. Once again, Laura Herdman and her colleagues at Capital Law provided exemplary legal advice and support during this process. I look forward very much to working with Laura again during 2018 as PulmonIR seeks to secure further investment to carry out our ambitious product development and regulatory approval plans.’
Laura Herdman, our Corporate Associate who advised Pulmon IR, said, ‘it’s brilliant to be able to help such a fantastic medical tech company as they develop their business and go from strength to strength. We assist PulmonIR with all their legal requirements, and Mark and Paul are an absolute pleasure to work with – we’re looking forward to playing a part in their growth over the coming years.'
Swansea-based medical device company PulmonIR has been given a grant of £105,000 by Innovate UK. The company, which was spun out from Swansea University, focuses on detecting and monitoring lung disease and will use the funding to carry out product development work before running extended clinical trials and securing regulatory approvals for its medical technology in the UK, EU, US and China. PulmonIR’s development plans are supported by access to a portfolio of patent applications relating to the use of infrared spectroscopy to diagnose and monitor respiratory conditions including chronic obstructive pulmonary disease (COPD) and lung cancer.